Provided by Tiger Trade Technology Pte. Ltd.

Novartis AG

154.65
-2.8900-1.83%
Post-market: 154.650.00000.00%17:48 EDT
Volume:1.22M
Turnover:189.46M
Market Cap:295.07B
PE:23.38
High:155.93
Open:155.93
Low:154.43
Close:157.54
52wk High:170.46
52wk Low:121.57
Shares:1.91B
Float Shares:1.85B
Volume Ratio:1.02
T/O Rate:0.07%
Dividend:4.67
Dividend Rate:3.02%
EPS(TTM):6.61
EPS(LYR):7.15
ROE:30.35%
ROA:10.25%
PB:7.10
PE(LYR):21.63

Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), Insulet (PODD) and Novartis (NVS)

TIPRANKS
·
Jun 12

Sector Update: Healthcare Stocks Rise Thursday Afternoon

MT Newswires Live
·
Jun 12

Movement Alert|Novartis Rises 3.11% in Pre-Market Trading, Multiple Pipeline Catalysts Drive Positive Sentiment

Market Focus
·
Jun 11

Bank of America Securities Remains a Buy on Novartis (NVS)

TIPRANKS
·
Jun 11

Novartis announces biomarker cohort in study of del-brax met primary endpoint

TIPRANKS
·
Jun 11

Novartis Says Early-to-Mid Stage Study for Muscular Dystrophy Drug Meets Main Goal

MT Newswires Live
·
Jun 11

Novartis $12 Billion Bet on Avidity Is Starting to Pay Off -- Market Talk

Dow Jones
·
Jun 11

Novartis Could Move Forward Neuromuscular Drug Approval After Early Data -- Market Talk

Dow Jones
·
Jun 11

Europe's Big Pharma Could Win Investors' Favor With Busy End of Year -- Market Talk

Dow Jones
·
Jun 10

Why a U.K. pharma giant is paying a 40% premium to pivot back to oncology

Dow Jones
·
Jun 09

GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down

Dow Jones
·
Jun 09

Argus Research Reaffirms Their Buy Rating on Novartis (NVS)

TIPRANKS
·
Jun 06

Movement Alert|Novartis Rises 3.13% in Regular Trading, Positive Cosentyx Phase 3 Data Boosts Shares Amid Broad Pharma Rally

Market Focus
·
Jun 05

Novartis Says Cosentyx Shows Sustained Remission in Phase 3 Trial

MT Newswires Live
·
Jun 04

Celcuity Says Gedatolisib Outperforms Novartis' Alpelisib Plus Fulvestrant in Phase 3 Trial

MT Newswires Live
·
Jun 03

Movement Alert|Novartis Falls 3.06% in Regular Trading, Trading at $144.97

Market Focus
·
Jun 01

Novartis's Next Prostate Cancer Therapy Could Raise Bar for Treatment -- Market Talk

Dow Jones
·
Jun 01

Novartis announces results on rPFS improvements across subgroups with Pluvicto

TIPRANKS
·
Jun 01

Experimental Novartis radiopharma drug shows promise in early study

Reuters
·
May 31

A New, Powerful Cholesterol-Lowering Drug Is on the Horizon -- WSJ

Dow Jones
·
May 28